Pre-earnings options volume in Cidara Therapeutics is 3.0x normal with calls leading puts :. Implied volatility suggests the market is anticipating a move near 21.4%, or 31c, after results are released. Median move over the past eight quarters is 2.5%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CDTX:
- Biotech Alert: Searches spiking for these stocks today
- Cidara Therapeutics reports Q4 EPS (19c), consensus (17c)
- Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- Cidara Therapeutics Drops Even as FDA Approves Rezzayo
- Cidara Therapeutics and Melinta Therapeutics’ Rezzayo approved by FDA